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A simple, rapid, sensitive and precise 
High Performance Liquid Chromatographic 
(HPLC) method has been developed for the 
estimation of gatifloxacin in its pharmaceutical 
dosage forms. In this method RP-C18 column 
(150mmx4.6mm I.D., 5 m particle size) with 
mobile phase consisting of acetonitrile and 0.05M 
phosphate buffer in the ratio of 25:75 v/v in 
isocratic mode was used. The detection wavelength 
is 293nm and the flow rate is 0.8ml/min. 
Ciprofloxacin is used as internal standard. The 
linearity was found to be in the range of 0.1 to 10 
g/ml and shows a correlation coefficient of 
0.9999. The intra- and inter-day variation was 
found to be less than 1.2% showing high precision 
of the assay method. The mean percent recovery of 
the drug from the solution containing 4 g/ml was 
100.5  2.06 indicating high accuracy of the 
proposed method. Hence, this method is simple, 
fast, specific, accurate, precise and less time 
consuming for the estimation of gatifloxacin in 
pharmaceutical dosage forms.  
Keywords: HPLC, Gatifloxacin, Estimation, 
Pharmaceutical dosage forms. 
INTRODUCTION 
Gatifloxacin(GTF)1 is a broad-spectrum 
antimicrobial fluoroquinolone that is active against 
both gram-positive and gram-negative bacteria, is 
used in the treatment of wide range of infections. 
Chemically GTF2 is 1-Cyclopropyl-6-fluoro-1,4-
dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-
oxo-3-quinolonecarboxylicacid. GTF acts by 
inhibiting bacterial DNA synthesis by inhibiting 
DNA gyrase3. Literature survey reveals that a few 
methods based on Spectrophotometric4, 
Spectrofluorimetric5, HPTLC6 and HPLC7-15 have 
been reported for the determination of GTF. In 
this present study a simple, rapid, accurate, 
sensitive and precise HPLC method was developed 
for the estimation of GTF in pharmaceutical 
dosage forms. 
EXPERIMENTAL 
GTF was a gift sample from M/s 
Panacea Biotec. Ltd., New Delhi and Ciprofloxacin 
was a gift sample from M/s Dr. Reddy’s Lab Ltd., 
Hyderabad. Acetonitrile of HPLC grade (E-Merck) 
and Triple distilled water was used. All other 




Instrumentation   
Quantitative HPLC was performed on a 
HPLC pump Waters Breeze system with Waters 
1500 series HPLC pump, Waters 2487 dual 
absorbance detector and RP-C18 column 
(150mmx4.6mm I.D., 5 m particle size) was used. 
The HPLC system was equipped with Waters 
Breeze Software.  
HPLC Conditions 
The contents of the mobile phase were 
acetonitrile and 0.05M phosphate (KH2PO4) buffer 
(pH adjusted to 3.0 with orthophosphoric acid) 
were filtered through a 0.45 m membrane filter 
before use, degassed and were pumped from the 
solvent reservoir in the ratio of 25:75 v/v into the 
column at a flow rate of 0.8ml/min. The run time 
was set at 6 minutes. The volume of injection loop 
was 20 l prior to injection of the drug solution the 
column was equilibrated for atleast 30 min. with 
the mobile phase flowing through the system.  
Preparation of Stock solution 
Stock solution of GTF drug and internal 
standard were prepared by dissolving 100 mg of 
GTF and ciprofloxacin separately in 100 ml 
volumetric flasks containing 50 ml of 0.1M HCl (50 
ml of water incase of ciprofloxacin) and then made 
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mark. Daily working standard solutions of GTF 
and ciprofloxacin were prepared by suitable 
dilutions of the stock solution with the mobile 
phase.  
Calibration solutions 
Nine sets of the GTF solutions were 
prepared in mobile phase at concentrations of 0.1, 
0.2, 0.4, 0.6, 1, 2, 4, 6 and 10 g/ml along with a 
fixed concentration (4 g/ml) of ciprofloxacin as 
internal standard. 
Procedure  
The standard solutions prepared as above 
were filtered through 0.45 m membrane filter and 
the filterate was injected (20 l) six times into the 
column at a flow rate of 0.8 ml/min. The ratio of 
GTF peak area to that of internal standard for each 
of the drug concentrations was calculated. The 
regression of the GTF concentration over the ratio 
of GTF peak area to that of internal standard was 
obtained. This regression was used to estimate the 
amount of GTF in pharmaceutical dosage forms. 
GTF solutions containing 2 g/ml, 4 g/ml and 6 
g/ml were subjected to the proposed HPLC 
analysis for finding out the intra- and inter-day 
variations. The recovery studies were carried out 
by adding known amount of GTF to the 
preanalysed samples and subjecting them to the 
proposed HPLC method.  
Estimation of GTF in Pharmaceutical dosage 
forms 
Tablets: Twenty tablets were weighed and 
powdered. An accurately weighed portion of the 
powder, equivalent to 100 mg of GTF was 
transferred to a 100 ml volumetric flask containing 
50 ml of 0.1M HCl. The contents of the flask were 
sonicated to dissolve GTF, made upto volume to 
get a solution of 1 mg/ml and the resulting 
solution was filtered through 0.45 m membrane 
filter. 
Injections: An aliquot of injection equivalent to 
100 mg of GTF was transferred into a 100 ml 
volumetric flask and volume was made upto 100 ml 
with a 0.1M HCl to get a solution of 1 mg/ml. 
Further dilutions were made with mobile phase to 
get a working standard solution of 100 g/ml.  
Aliquots of this solution was transferred 
to volumetric flasks and made upto sufficient 
volume with mobile phase to give an expected 
concentration along with a fixed concentration  
(4 g/ml) of internal standard. This solution (20 
l) was injected six times into the column. The 
mean values of peak area ratio of GTF to internal 
standard of six such determinations were calculated 
and the GTF content in the tablet and injection 
dosage forms were quantified using the regression 
equation obtained below. The same procedure was 
used to estimate the concentration of the GTF in 
two more commercial brands.  
 
RESULTS AND DISCUSSION 
The present study was carried out to 
develop a specific, sensitive, precise and accurate 
HPLC method for the analysis of GTF in 
pharmaceutical dosage forms. A typical 
chromatogram is shown in Fig. 1. The retention 
times for GTF and internal standard 
(ciprofloxacin) were 3.21 and 2.48 min respectively. 
Each of the samples were injected five times and 
the same retention times were observed in all cases. 
The ratio of peak area of GTF to peak area of 
internal standard for different concentrations as 
above were calculated and the average values for 
six such determinations are shown in Table 1. The 
peak areas of both the GTF and internal standard 
were reproducible as indicated by low coefficient of 
variation (0.42 %). A good linear relationship (r = 
0.9999) was observed between the concentration of 
GTF and the respective ratio of peak areas. The 
regression of GTF concentration over its peak area 
ratio was found to be Y = 0.0061 + 0.6083X 
(Where Y = ratio of peak area of GTF to that of 
internal standard; X = concentration of GTF) in 
the range of 0.1-10 g/ml. 
When GTF solution containing 2, 4 and 
6 g/ml were analysed by the proposed HPLC 
method for finding out intra- and inter-day 
variation, a low coefficient of variation was 
observed (Table 2). This shows that the present 
HPLC method is highly precise. The amounts of 
GTF from the preanalysed samples containing 
known amounts of the GTF are shown in Table 3. 
About 100.5 % of GTF could be recovered from the 
preanalysed samples indicating the high accuracy 
of the proposed HPLC method. 
The GTF content in the pharmaceutical 
dosage forms tablets and injections were quantified 
using the proposed analytical method. The mean 
content of GTF in four brands of dosage forms are 
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peaks indicates no interference of the excipients 
used in the dosage forms. The dosage forms were 
found to contain 103.37 to 104.25 % of the labelled 
amount. The low % CV indicates the 





Fig. 1: Typical Chromatogram of Gatifloxacin 
Table 1: Calibration of the HPLC method for the estimation of GTF 
Concentration of GTF  
( g/ml) 
Mean peak area ratio  
(n = 6) 
% CV 
0.1 0.0682 0.95 
0.2 0.1265 0.42 
0.4 0.2504 0.47 
0.6 0.3772 0.54 
1 0.6020 0.36 
2 1.2242 0.97 
4 2.4662 1.21 
6 3.6255 0.44 
10 6.0984 1.53 
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Table 2: Precision of the proposed HPLC method  
GTF concentration 
( g/ml) 
Concentration of GTF ( g/ml) found on 
Intra-day Inter-day 
Mean (n = 6) (%) CV Mean (n = 6) (%) CV 
2 2.15 0.93 2.05 1.20 
4 4.07 1.75 3.98 0.97 
6 6.12 1.21 6.03 0.73 
 
Table 3: Recovery of GTF 
Amount of drug added ( g) Mean amount found (n = 6) Mean % of recovery (n = 
6) 
2 1.99  0.02 99.5  1.0 
4 4.02  0.08 100.5  2.06 
6 5.98  0.10 99.6  1.6 
 
Table 4: Assay of GTF in different dosage forms 
Dosage form Labelled 
amount (mg) 
Mean amount found (mg) by 
the proposed method (n=6) 
Mean % labelled 
amount (n = 6) 
Tab-I 400 413.5  0.10 103.37  0.03 
Tab-II 200 207.25  0.15 103.625  0.12 
Inj-I 400 417  0.07 104.25  0.01 
Inj-II 400 415.3  0.29 103.82  0.01 
CONCLUSION 
The proposed HPLC method enables 
quantitative determination of third generation 
fluoroquinolones such as gatifloxacin in 
pharmaceutical dosage forms. Preparation of 
samples is easy and efficient. UV detection at 
293nm was found to be suitable without any 
interference from tablets or injections excipients or 
solvents. All calibration curves were found to be 
linear with correlation coefficient of 0.9999. 
Analytical results of samples were in accordance 
with those of standard solution in the same 
concentrations. The proposed HPLC method is 
simple, specific, sensitive, accurate and precise and 
can be used in routine analysis in quality control 
laboratories. 
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